Pragmatic, Randomized Optimal Platelet and Plasma Ratios

 

Objective

...extensive lab analysis will be done to evaluate the influence of fluid resuscitation on traumatic induced coagulopathy."

This trial was sponsored by the National Heart Lung and Blood Institute and the Defence Research and Development Canada and the Resuscitation Outcomes Consortium (ROC), led by Gerald van Belle, PhD, MA.

PROPPR was a multi-center, randomized trial which compared different ratios of blood products given to trauma patients who were predicted to require massive transfusions (greater than 10 units of PRBCs within the first 24 hours). The patients who have been predicted to require a massive transfusion  received blood products based on a 1:1:1 or 1:1:2 ratio of platelets, plasma and red blood cells. A total of 680 patients were enrolled into this study from 12 participating sites in the United States and Canada.

In addition to evaluating the patient outcomes based on ratio of products, extensive lab analysis was done to evaluate the influence of fluid resuscitation on traumatic induced coagulopathy. The PROPPR trial was conduced under exception from informed consent. The trial began in August of 2012 and concluded enrollment on December 2, 2013. Data analysis is complete.

The HCCC (Houston Clinical Coordinating Center) will be lead by John Holcomb, M.D. His group will be responsible for the overall clinical coordination for this study. Barbara Tilley, Ph.D. will lead the HDCC (Houston Data Coordinating Center). Dr. Tilley and her group will be responsible for the data coordination, maintenance, and analysis for this study.